Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Futura Medical plc (LSE:FUM) in Focus: What AIM and London Market Investors Should Watch Next

Futura Medical plc (LSE:FUM) is in focus as investors assess recent company developments, execution and the next set of measurable business milestones.

Ankur Sharma | 13 October 2026

Optima Health plc (LSE:OPT) in Focus: What AIM and London Market Investors Should Watch Next

Optima Health plc (LSE:OPT) is in focus as investors assess recent company developments, execution and the next set of measurable business milestones.

Ankur Sharma | 13 October 2026

How hVIVO (LSE:HVO) Plans a Second-Half Rebound Within the FTSE AIM All Share Index

hVIVO runs human challenge studies, in which volunteers are deliberately exposed to a pathogen under controlled conditions to test vaccines and antivirals. It operates from London and also offers laboratory, early-phase clinical and patient recruitment services. The group now trades under a single hVIVO …

Ankur Sharma | 13 October 2026

Why ImmuPharma (LSE:IMM) is focused on a P140 partnering deal, and how it fits within the FTSE AIM All Share Index

ImmuPharma is a specialist drug discovery and development company. Its lead asset is P140, also known as Lupuzor or forigerimod, a peptide being developed for autoimmune and inflammatory diseases. Kapiglucagon is a wholly owned glucagon prodrug designed to allow stable liquid formulations, mainly for …

Ankur Sharma | 13 October 2026

Thalia Therapeutics PLC (LSE:THAT): FTSE AIM All-Share Stock in Focus as Investors Weigh the Next Catalyst

Thalia Therapeutics PLC (LSE:THAT) is being assessed against its exposure to life-sciences investment and therapeutic development.

Ankur Sharma | 13 October 2026

Verici Dx (LSE:VRCI): £8.75m Fundraising Reopens Trading and Resets the Clinical Growth Runway

The stock sits within the wider London Stock Exchange AIM market and the FTSE AIM All-Share universe. For smaller listed companies, investor attention can shift quickly when a company reports a financing, operating update, project milestone or strategic decision. The index context is useful …

Ankur Sharma | 13 October 2026

Proteome Sciences plc (LSE:PRM): AIM Market Spotlight as Investors Assess Demand For Outsourced Proteomics

Proteome Sciences plc (LSE:PRM) is an AIM-traded company whose investment case centres on proteomics services and biomarker research. The current market discussion is shaped by demand for outsourced proteomics and diagnostics research. The central question for investors is whether strategic progress can translate into …

Ankur Sharma | 13 October 2026

Abingdon Health (LSE:ABDX) Final Results Put Test Demand, Manufacturing and Cash Conversion in Focus

Abingdon Health (LSE:ABDX) is in focus following its final results announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to judge whether the announcement can create lasting value. …

Ankur Sharma | 13 October 2026

Aptamer Group (LSE:APTA) Full-Year Results Put Revenue Conversion and Cash Runway in Focus

Aptamer Group (LSE:APTA) is in focus following its full-year results for the 12 months to 30 june 2026 announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to …

Ankur Sharma | 13 October 2026

Emv Capital (LSE:EMVC) Brings Glycotest Licensing Deal Into Focus for Healthcare Investors

Emv Capital (LSE:EMVC) is in focus following its glycotest intellectual-property licensing announcement announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to judge whether the announcement can create …

Ankur Sharma | 13 October 2026
Support

Hi! How can we help you today?

Loading…